Andersons pediatric cardiology 2345

Cyclooxygenase,incontrolofcirculation,1358
Cyclosporine,forKawasakisyndrome,990
CYP2C9,1432–1434
CYP2C19,1434
CYP2D6,1431–1432
CYP3A,1434
Cysticfibrosis,exercisetestingin,402
Cysts,pericardial,1075
Cytogenetics,56
Cytotrophoblasts,157–158
D
Dacron,220–221
Dallascriteria,inmyocarditis,1175
Damus-Kaye-Stansel(DKS)procedure,1280–1281,1281–1282,1281f
Danondisease(DD),80
hypertrophiccardiomyopathyand,1147–1148

Daptomycin,forinfectiveendocarditis,1053t
Data
accuracyof,410
analysisof,410–415
planfor,411
relationshipsbetweenvariablesand,411

reliabilityof,410
validityof,409–410
variablesand,descriptionof,411

Dataregistries,incongenitalcardiaccare,1510,1511t–1514t
Datasources,incongenitalcardiaccare,1509–1510
Database,403

DC,Dilatedcardiomyopathy
DCD,Donationaftercirculatorydeath
DD,Danondisease
Deaddonorrule,incardiactransplantation,1476–1477
Death,ofchild,1463
Decisionauthority,ethicalissuesand,1472
Decisionsupporttools,1438,1439f
Decisionalauthority,1469t
Decision-making,shared,ethicalissuesand,1471
Decreasedcentralnervousmaturity,incongenitalbraindisease,1396
Deephypothermiccirculatoryarrest,incardiopulmonarybypass,230–231
Defibrillation,335–378
Defibrillators,364–366
cardioverter,implantable,366–367,366f,368f

Delayedsternalclosure,managementof,inFontanpathway,1290
Deletion8P23syndrome,1410,1410f–1411f,1410t
Deletion22q11.2,1410–1411,1411t
Denominator,definitionof,173–174
Dependentvariables,410–411
Descendingaorta,indiagnosticcatheterization,251
Developingheart,physiologyof,83–107,Fetalheart
Development,followingcardiactransplantation,1238
Developmentalcare,forprematurity,211–212
Developmentaldisability,geneticsusceptibilityto,1397
Developmentalservices,forcomplexcongenitalcardiacdisease,1402,1402b
Development-specializedmachinery,ofcardiomyocyte,71–77
actinandtitin,72–73

excitationandcontraction,75–77,76f
mitochondriaandenergyproduction,74–75,75f
myosin,71–72
sarcomere,71,71f
troponin,73–74

Devices,removalof,inpulmonaryvenousstenosis,interventionaltechniques
for,274–275
Dexamethasone,forantibody-mediatedfetalheartdisease,143–144,144f
Dexmedetomidine,1549
Dexrazoxane,forcancertherapy-relatedcardiotoxicity,1171
Dextrocardia,917
Dextroposition,917
Dextroversion,917
Diabetes,type1,systemicarterialdysfunctionand,1371
Diabetesmellitus,cardiacinvolvementin,1095–1096
Diagnosis,researchstudieson,criticalappraisalof,421–422
Diagnosis-based,forintegratedcarepathways,1482t
Diagnosticcatheterization
anatomicapproachin,243–252
anesthesiain,239
angiographicevaluationin,242–243,243t
inaorta,251
inaorticvalveapparatus,250
inatrialseptum,245–246
inazygousvein,244,245f
cathetersfor,240
complexcongenitalheartlesionsin,252

incoronaryarteries,250–251
equipmentfor,240
infemoralvein,243–244
hearttransplantpatientsin,251–252